The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus ...

Detailed price information for Theralase Technologies Inc (TLT-X) from The Globe and Mail including charting and trades.

A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

Discover how Abu Dhabi's Sheikh Shakhbout Medical City transformed the life of chef Mandhish Gomez, who endured over 20 years ...

An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...

The number and frequency of intravesical instillations for non-muscle-invasive bladder cancer (NMIBC) impairs quality of life and needs to be reported in clinical trials.

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the disease.The ongoing SunRISe-3 trial (NCT05714202) is testing TAR-200 head-to-head ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

Pharmaceutical drugs developed by two local companies received approvals in the European Union last month. On Dec. 12, Culver ...

Urothelial tumours represent the 6th most frequent cancer in men and its incidence continues to rise in both sexes. Fortunately, approximately 75% of ...

Intuitive Surgical, Inc. stock: da Vinci robotics leader with 80% share, recurring revenue, fast procedure growth and solid ...